IL121299A - History 4 - Droxy-piperidine, the process for their preparation and the pharmaceutical preparations containing them - Google Patents

History 4 - Droxy-piperidine, the process for their preparation and the pharmaceutical preparations containing them

Info

Publication number
IL121299A
IL121299A IL12129997A IL12129997A IL121299A IL 121299 A IL121299 A IL 121299A IL 12129997 A IL12129997 A IL 12129997A IL 12129997 A IL12129997 A IL 12129997A IL 121299 A IL121299 A IL 121299A
Authority
IL
Israel
Prior art keywords
hydroxy
piperidin
compound
benzyl
formula
Prior art date
Application number
IL12129997A
Other languages
English (en)
Hebrew (he)
Other versions
IL121299A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL121299A0 publication Critical patent/IL121299A0/xx
Publication of IL121299A publication Critical patent/IL121299A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12129997A 1996-07-19 1997-07-14 History 4 - Droxy-piperidine, the process for their preparation and the pharmaceutical preparations containing them IL121299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111660 1996-07-19
EP97105366 1997-04-01

Publications (2)

Publication Number Publication Date
IL121299A0 IL121299A0 (en) 1998-01-04
IL121299A true IL121299A (en) 2001-12-23

Family

ID=26142078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12129997A IL121299A (en) 1996-07-19 1997-07-14 History 4 - Droxy-piperidine, the process for their preparation and the pharmaceutical preparations containing them

Country Status (34)

Country Link
US (1) US5889026A (fr)
EP (1) EP0824098B1 (fr)
JP (1) JP3179050B2 (fr)
KR (1) KR100235804B1 (fr)
CN (1) CN1120154C (fr)
AR (2) AR007897A1 (fr)
AT (1) ATE207899T1 (fr)
AU (1) AU719352B2 (fr)
BR (1) BR9704031A (fr)
CA (1) CA2210044C (fr)
CO (1) CO4900064A1 (fr)
CZ (1) CZ290898B6 (fr)
DE (1) DE69707782T2 (fr)
DK (1) DK0824098T3 (fr)
ES (1) ES2164967T3 (fr)
HK (1) HK1009124A1 (fr)
HR (1) HRP970394A2 (fr)
HU (1) HUP9701194A3 (fr)
ID (1) ID19632A (fr)
IL (1) IL121299A (fr)
MA (1) MA24274A1 (fr)
MX (1) MX9705387A (fr)
NO (1) NO308657B1 (fr)
NZ (1) NZ328330A (fr)
PE (1) PE86398A1 (fr)
PL (1) PL321201A1 (fr)
PT (1) PT824098E (fr)
RU (1) RU2178412C2 (fr)
SG (1) SG60085A1 (fr)
TR (1) TR199700659A2 (fr)
TW (1) TW498067B (fr)
UY (1) UY24625A1 (fr)
YU (1) YU30197A (fr)
ZA (1) ZA976224B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
AR020590A1 (es) * 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
WO2000031033A1 (fr) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Antagonistes du recepteur de piperidine ccr-3
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
EP1674087A1 (fr) 2000-10-02 2006-06-28 Pfizer Products Inc. Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CA2440284A1 (fr) * 2001-03-08 2002-09-19 Emory University Antagonistes du recepteur nmda dependant du ph
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
AU2002360436A1 (en) * 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
US6916804B2 (en) * 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
WO2005030720A1 (fr) * 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Derive de piperidine presentant une activite antagoniste du recepteur ndma
EP1680127B1 (fr) * 2003-10-23 2008-10-15 F. Hoffmann-La Roche Ag Derives de benzazepine utiles comme inhibiteurs de mao-b
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
CA2693032A1 (fr) * 2007-06-29 2009-01-08 Emory University Antagonistes des recepteurs nmda pour la neuroprotection
US7869022B2 (en) 2007-07-18 2011-01-11 Asml Netherlands B.V. Inspection method and apparatus lithographic apparatus, lithographic processing cell, device manufacturing method and distance measuring system
EP2296658A4 (fr) * 2008-05-09 2014-01-15 Univ Emory Antagonistes des récepteurs nmda utilisables pour le traitement de troubles neuropsychiatriques
US7874106B2 (en) * 2009-02-13 2011-01-25 Ykk Corporation Of America Sill flashing and end dam assembly
PT2995306T (pt) * 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
ES2814178T3 (es) * 2009-10-19 2021-03-26 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
EP3233799B1 (fr) 2014-12-19 2021-05-19 The Broad Institute, Inc. Ligands du récepteur d2 de la dopamine
WO2016100940A1 (fr) 2014-12-19 2016-06-23 The Broad Institute, Inc. Ligands des récepteurs dopaminergiques d2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356905A (en) * 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
TW281670B (fr) * 1993-09-02 1996-07-21 Hoffmann La Roche
NZ275151A (en) * 1994-01-31 1998-02-26 Pfizer 3r*4s*3-[4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4 ,7-diol; isomers and salts
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists

Also Published As

Publication number Publication date
MA24274A1 (fr) 1998-04-01
KR980009244A (ko) 1998-04-30
YU30197A (sh) 1999-12-27
HUP9701194A2 (hu) 1999-05-28
MX9705387A (es) 1998-01-31
NZ328330A (en) 1998-05-27
CO4900064A1 (es) 2000-03-27
ZA976224B (en) 1998-01-19
JP3179050B2 (ja) 2001-06-25
TW498067B (en) 2002-08-11
CZ227497A3 (cs) 1998-02-18
UY24625A1 (es) 2000-12-29
AU719352B2 (en) 2000-05-04
TR199700659A2 (xx) 1998-02-21
HU9701194D0 (en) 1997-09-29
EP0824098B1 (fr) 2001-10-31
KR100235804B1 (ko) 1999-12-15
HRP970394A2 (en) 1998-06-30
BR9704031A (pt) 1998-12-29
HUP9701194A3 (en) 1999-06-28
AR007897A1 (es) 1999-11-24
CZ290898B6 (cs) 2002-11-13
IL121299A0 (en) 1998-01-04
ID19632A (id) 1998-07-23
NO973337D0 (no) 1997-07-18
DE69707782T2 (de) 2002-06-20
CA2210044A1 (fr) 1998-01-19
EP0824098A1 (fr) 1998-02-18
DE69707782D1 (de) 2001-12-06
PT824098E (pt) 2002-04-29
PE86398A1 (es) 1998-12-10
US5889026A (en) 1999-03-30
PL321201A1 (en) 1998-02-02
RU2178412C2 (ru) 2002-01-20
HK1009124A1 (en) 1999-05-28
CN1171396A (zh) 1998-01-28
CN1120154C (zh) 2003-09-03
AR007898A1 (es) 1999-11-24
NO308657B1 (no) 2000-10-09
ES2164967T3 (es) 2002-03-01
NO973337L (no) 1998-01-20
DK0824098T3 (da) 2002-02-18
CA2210044C (fr) 2006-02-14
AU2875697A (en) 1998-01-29
JPH1067742A (ja) 1998-03-10
ATE207899T1 (de) 2001-11-15
SG60085A1 (en) 1999-02-22

Similar Documents

Publication Publication Date Title
EP0824098B1 (fr) Dérivés de la 4-hydroxypipéridine
MXPA97005387A (en) Derivatives of the 4-hidroxi-piperid
DE69430861T2 (de) N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
RU2188194C2 (ru) Производные имидазола и фармацевтически приемлемая композиция
KR100384979B1 (ko) 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6683097B2 (en) Imidazole derivatives
SK82498A3 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
CA2454613A1 (fr) Piperidines aniliniques substituees, utilisees comme antagonistes selectifs de la mch
JP2001525406A (ja) 新規な化合物
IL189453A (en) History of Carboxamide and Neutril, Pharmaceutical Preparation, History of Use as a Drug, History of Use for Drug Production, History of Other Therapeutic Compound, and Intermediate Material for Preparation of History
EP0306440A2 (fr) 1-Phényl-1H-imidazoles substitués en C-4 du groupe phényle comme agents cardiovasculaires
EP0846683B1 (fr) Dérivés de la 4-hydroxypipéridine
WO2006010966A1 (fr) Nouveaux derives d'uree benzoyle
CA2376091C (fr) Derives d'ethanesulfonyl-piperidine
US6359138B1 (en) 4-hydroxy-piperidine derivatives
OA11235A (en) Quatenary ammonium compounds as tachykinin antagonists
EP0741722B1 (fr) Derives de triazole
JPH06340627A (ja) ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force